{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-2.04","upperLimit":"4.36","value":"1.16"},{"groupId":"OG001","lowerLimit":"-4.38","upperLimit":"2.39","value":"-1.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"86"}],"units":"Participants"}],"description":"Change in the Total Symptom Score which assessed improvement in disease symptoms measured by the change in TSS from the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) instrument being used in this study from baseline to 12 months. This 19 item instrument includes the previously validated 9 item brief fatigue inventory (BFI), symptoms related to splenomegaly, inactivity, cough, night sweats, pruritus, bone pains, fevers, weight loss, and an overall quality of life assessment. Each item is scored from 0-10 with full scale from 0-190, with higher scores mean worse symptoms.","dispersionType":"Full Range","groups":[{"description":"The subject received the PEGASYS at a dose level of 45 micrograms weekly and gradually increased to the maximum dose of 180 micrograms per week. The dose was administered by prefilled syringes and injected subcutaneously. Subjects received therapy for up to 12 months.\n\nAspirin: Subject asked to take 81 to 100mg per day for the 12 months of the study treatment.","id":"OG000","title":"PEGASYS"},{"description":"Subjects received a 500mg tablet to be taken twice daily for up to 12 months of treatment.\n\nAspirin: Subject asked to take 81 to 100mg per day for the 12 months of the study treatment.","id":"OG001","title":"Hydroxyurea"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"baseline and 12 months","title":"Change in the Total Symptom Score (TSS)","type":"SECONDARY","unitOfMeasure":"score on a scale"}